{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:24:22Z","timestamp":1787383462619,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM22041"],"award-info":[{"award-number":["LSHM22041"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["80-83600-98-3074"],"award-info":[{"award-number":["80-83600-98-3074"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jad.2026.122265","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:02:13Z","timestamp":1784246533000},"page":"122265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial"],"prefix":"10.1016","volume":"413","author":[{"given":"Sara","family":"Massetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Y.","family":"Smith-Apeldoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien K.E.","family":"Veraart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Muller Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni T.","family":"Tzavara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Meerlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens H.","family":"van Dalfsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.122265_bb0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jad.2015.06.033","article-title":"Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT","volume":"186","author":"Allen","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122265_bb0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122265_bb0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/JCP.0000000000001049","article-title":"Prior antidepressant treatment trials may predict a greater risk of depressive relapse during antidepressant maintenance therapy","volume":"39","author":"Amsterdam","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0020","series-title":"DSM-5 (Diagnostic and Statistical Manual of Mental Disorders)","author":"APA","year":"2013"},{"key":"10.1016\/j.jad.2026.122265_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jad.2026.122265_bb0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pnpbp.2004.11.009","article-title":"The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study","volume":"29","author":"Aydemir","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0035","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ceb.2011.09.002","article-title":"Cell atrophy and loss in depression: reversal by antidepressant treatment","volume":"23","author":"Banasr","year":"2011","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.jad.2026.122265_bb0040","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bph.15753","article-title":"Novel drug developmental strategies for treatment-resistant depression","volume":"179","author":"Borb\u00e9ly","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpsychires.2020.07.045","article-title":"Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression","volume":"130","author":"Bruijniks","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122265_bb0050","first-page":"e20210298","article-title":"Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial","volume":"45","author":"Caliman-Fontes","year":"2023","journal-title":"Trends Psychiatry Psychother."},{"key":"10.1016\/j.jad.2026.122265_bb0055","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105159","article-title":"The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: insight from meta-analyses","volume":"149","author":"Cavaleri","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2026.122265_bb0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.psc.2023.02.010","article-title":"Immune dysregulation in treatment-resistant depression: precision approaches to treatment selection and development of novel treatments","volume":"46","author":"Chin Fatt","year":"2023","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.jad.2026.122265_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2014.00189","article-title":"A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy","volume":"8","author":"Coplan","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.jad.2026.122265_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214445","article-title":"BDNF as a mediator of antidepressant response: recent advances and lifestyle interactions","volume":"23","author":"Cubillos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jad.2026.122265_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110609","article-title":"Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: highlighting their potential for transdiagnostic therapeutics","volume":"119","author":"Driver","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","article-title":"Signaling pathways underlying the rapid antidepressant actions of ketamine","volume":"62","author":"Duman","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2026.122265_bb0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejn.14630","article-title":"Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants","volume":"53","author":"Duman","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jad.2026.122265_bb0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1461145712000545","article-title":"Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder","volume":"16","author":"Duncan","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0105","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1113\/EP091671","article-title":"Circadian rhythm of brain-derived neurotrophic factor in serum and plasma","volume":"109","author":"Ehrhardt","year":"2024","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.jad.2026.122265_bb0110","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.pnpbp.2010.07.026","article-title":"The mechanisms of tolerance in antidepressant action","volume":"35","author":"Fava","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jad.2017.07.001","article-title":"Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks","volume":"233","author":"Gadad","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122265_bb0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2026.122265_bb0125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jad.2019.04.096","article-title":"Functional disconnectivity of the hippocampal network and neural correlates of memory impairment in treatment-resistant depression","volume":"253","author":"Ge","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122265_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajp.2015.10.006","article-title":"Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine","volume":"18","author":"Ghosh","year":"2015","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2026.122265_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320922474","article-title":"Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study","volume":"10","author":"Glue","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","article-title":"Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression","volume":"17","author":"Haile","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jpsychires.2016.07.011","article-title":"Frequency-specific alterations in functional connectivity in treatment-resistant and -sensitive major depressive disorder","volume":"82","author":"He","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122265_bb0165","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/01621459.1987.10478551","article-title":"Fine-tuning some resistant rules for outlier labeling","volume":"82","author":"Hoaglin","year":"1987","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.jad.2026.122265_bb0170","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/01621459.1986.10478363","article-title":"Performance of some resistant rules for outlier labeling","volume":"81","author":"Hoaglin","year":"1986","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.jad.2026.122265_bb0175","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14740338.2022.2058488","article-title":"The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis","volume":"21","author":"Jawad","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2026.122265_bb0180","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuron.2020.05.015","article-title":"Targeting homeostatic synaptic plasticity for treatment of mood disorders","volume":"106","author":"Kavalali","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.jad.2026.122265_bb0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1461145710000738","article-title":"Blood BDNF concentrations reflect brain-tissue BDNF levels across species","volume":"14","author":"Klein","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000209350","article-title":"Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression","volume":"78","author":"Koch","year":"2009","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2026.122265_bb0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J. Chiropr. Med."},{"key":"10.1016\/j.jad.2026.122265_bb0200","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.biopsych.2012.05.031","article-title":"Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients","volume":"72","author":"Laje","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575607","article-title":"Platelets selectively regulate the release of BDNF, but not that of its precursor protein, proBDNF","volume":"11","author":"Le Blanc","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jad.2026.122265_bb0210","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0215","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41386-019-0391-y","article-title":"Acute psychosocial stress increases serum BDNF levels: an antagonistic relation to cortisol but no group differences after mental training","volume":"44","author":"Linz","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.122265_bb0220","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4088\/JCP.08m04659","article-title":"Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"70","author":"Machado-Vieira","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0225","article-title":"Biological correlates of treatment resistant depression: a review of peripheral biomarkers","volume":"14","author":"Mancuso","year":"2023","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.122265_bb0230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpsychires.2008.03.014","article-title":"Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine","volume":"43","author":"Matrisciano","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122265_bb0235","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","article-title":"Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis","volume":"27","author":"Medeiros","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0240","article-title":"Major challenges in youth psychopathology: treatment-resistant depression. A narrative review","volume":"15","author":"Menculini","year":"2024","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2026.122265_bb0245","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/15622975.2023.2169349","article-title":"Oral ketamine for depression: an updated systematic review","volume":"24","author":"Meshkat","year":"2023","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2026.122265_bb0255","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2026.122265_bb0260","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis","volume":"302","author":"Nu\u00f1ez","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122265_bb0265","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cpp.2539","article-title":"Exploring the effectiveness of a specialized therapy programme for burnout using subjective report and biomarkers of stress","volume":"28","author":"Orosz","year":"2021","journal-title":"Clin. Psychol. Psychother."},{"key":"10.1016\/j.jad.2026.122265_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313098","article-title":"Variations in BDNF and their role in the neurotrophic antidepressant mechanisms of ketamine and esketamine: a review","volume":"25","author":"Pardossi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jad.2026.122265_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063095","article-title":"What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study\u2019s patient-level data with fidelity to the original research p","volume":"13","author":"Pigott","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jad.2026.122265_bb0280","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jad.2014.11.044","article-title":"BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis","volume":"174","author":"Polyakova","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122265_bb0285","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14740338.2020.1776699","article-title":"Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence","volume":"19","author":"Rodrigues","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2026.122265_bb0290","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1192\/bjp.bp.115.165498","article-title":"Oral ketamine for the treatment of pain and treatment-resistant depression\u2020","volume":"208","author":"Schoevers","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 20","key":"10.1016\/j.jad.2026.122265_bb0295","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0300","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euroneuro.2020.09.633","article-title":"Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis","volume":"41","author":"Shi","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0305","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.15092","article-title":"Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body \u03b2-hydroxybutyrate","volume":"5","author":"Sleiman","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.jad.2026.122265_bb0310","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-019-2359-1","article-title":"Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial","volume":"19","author":"Smith-Apeldoorn","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0315","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"29","author":"Smith-Apeldoorn","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0320","series-title":"Exploratory Data Analysis","author":"Tuckey","year":"1977"},{"key":"10.1016\/j.jad.2026.122265_bb0325","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/02698811251332831","article-title":"Oral esketamine for patients with severe treatment-resistant depression: effectiveness, safety, and tolerability of a six-week open-label treatment program","volume":"39","author":"Veraart","year":"2025","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122265_bb0330","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov. Ment. Health"},{"key":"10.1016\/j.jad.2026.122265_bb0335","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jad.2026.122265_bb0340","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2026.122265_bb0345","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320973794","article-title":"Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation","volume":"10","author":"Zheng","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726011183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726011183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:43:35Z","timestamp":1787381015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726011183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":69,"alternative-id":["S0165032726011183"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122265","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122265"}}